ho166-dotmp
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 1999 (NCT00004158)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiodepletion
radiodepletion
Chemistry & pharmacology
- Payload
- 166-holmium
Oral
No
Parenteral
No
Topical
No
Also known as
- ho166-dotmp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00083564 | Phase 3 | Mar 1, 2004 | Poniard Pharmaceuticals |
| NCT00039754 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2002 | Poniard Pharmaceuticals |
| NCT00045136 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2002 | Poniard Pharmaceuticals |
| NCT00006234 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2001 | National Cancer Institute (NCI), University of Washington |
| NCT00008229 | Phase 3 | Aug 1, 2000 | National Cancer Institute (NCI), University of Washington |
| NCT00004158 | Phase 1/Phase 2 (Phase 2) | Jun 1, 1999 | National Cancer Institute (NCI), University of Washington |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 0 | 2 | 1999 |
| Poniard Pharmaceuticals | For profit | 3 | 3 | 2 | 2002 |
| University of Washington | Academic/Hospital | 3 | 3 | 2 | 1999 |
3 organizations
Page 1 / 1